Explores protein aggregation control through optimal strategies, inhibitors, and spatial regulation using liquid compartments, shedding light on drug interventions and aggregate dynamics.
Delves into the contrasting effects of chaperones on amyloid beta peptide aggregation, exploring inhibitors, oligomer quantification, and antibody impacts.
Explores beta-hairpins in polyglutamine protein aggregation, focusing on Huntington's disease and the molecular mechanisms behind toxic fibril formation.
Explores Alzheimer's disease, anxiety, pain, and the renin-angiotensin system, including the development of the first renin inhibitor for clinical treatment.
